AEON today
$0.17-$0.01 (-4.41%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourSymmetric Triangle
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $0.31
Key levels
Resistance$0.23
Resistance$0.19
Support$0.13
Latest news & SEC filings
ProductAEON Biopharma Files FDA Application For ABP-450 Testing
DealAEON Biopharma changes warrant terms, raising $6.2 million
AnalystLake Street keeps Buy rating on AEON Biopharma, lifts target to $2
All AEON news →About AEON Biopharma
AEON Biopharma develops ABP-450, a botulinum toxin complex, as a proposed biosimilar to Botox for treating medical conditions. It holds exclusive rights to develop and sell the product for therapeutic uses across North America, Europe, and certain other regions. The toxin is made by Daewoong Pharmaceutical in South Korea, and the same product is sold for cosmetic use in America under the Jeuveau brand. Its customers are physicians and healthcare providers who administer botulinum toxin treatments for conditions such as cervical dystonia, chronic migraine, and spasticity.
Based on the company's 10-K filed Mar 30, 2026.
· Healthcare
AEON Biopharma, Inc. (AEON)
What Is the Price Target for AEON?
SEPT Low Target
$1.36
SEPT Mid Target
$1.60
SEPT High Target
$1.84
Analyst Consensus
$1.60
Is AEON a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AEON.
Start Free Trial →Is AEON Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$1.60
17
Moat Score
NONE
4/9
Piotroski Score
-120.5
Altman Z-Score
What Is Smart Money Doing with AEON?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
UNCHANGED
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Daewoong Co., Ltd | 10% owner | Buy | 11,236,631 | $1K | Oct 30, 2026 |
| Daewoong Co., Ltd | 10% owner | Sale | 3,822 | $1K | Oct 30, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AEON Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
1561.52%
FCF Growth YoY
57.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for AEON
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AEON, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 13:40:43 | $0.18 | 2,000 | $$368 | SELL |
| 20:32:48 | $0.17 | 10,725 | $$2K | SELL |
| 19:11:35 | $0.17 | 1,500 | $$261 | BUY |
| 19:03:27 | $0.17 | 4,500 | $$788 | BUY |
| 19:01:44 | $0.17 | 1,000 | $$171 | SELL |
5 dark pool trades shown · $$3K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for AEON Biopharma, Inc. (AEON) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AEON — frequently asked questions
What is AEON stock price today?
AEON Biopharma, Inc. (AEON) is at $0.17, down 4.41% (-$0.01) at the Nov 11, 2026 close.
Why is AEON stock moving today?
Latest AEON news — Nov 9, 2026: AEON Biopharma Files FDA Application For ABP-450 Testing · Nov 3, 2026: AEON Biopharma changes warrant terms, raising $6.2 million
What is the AEON price target?
The average analyst price target for AEON is $1.60, ranging from $1 to $2, based on 2 analysts. Latest: Lake Street maintains on Oct 1, 2026.
What do analysts rate AEON?
Analyst ratings for AEON: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did AEON beat earnings?
AEON last reported on Aug 12, 2026: EPS -$0.02 vs -$0.23 expected — a beat of 91.1%.
What is AEON's P/E ratio?
AEON trades at a P/E of 0.0.
Does AEON pay a dividend?
AEON does not currently pay a dividend.
How much debt does AEON have?
AEON Biopharma, Inc. reported $13M of debt and $0M of cash (Dec 31, 2024).
What are AEON support and resistance levels?
Support: $0.13. Resistance: $0.19, $0.23, $0.31.
What are insiders doing with AEON?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on AEON?
Nov 9, 2026: AEON Biopharma Files FDA Application For ABP-450 Testing · Nov 3, 2026: AEON Biopharma changes warrant terms, raising $6.2 million · Oct 1, 2026: Lake Street keeps Buy rating on AEON Biopharma, lifts target to $2